Sandra and Edward Meyer Cancer Center

A set of powerful laboratory and computational techniques developed by scientists at Weill Cornell Medicine, the New York Genome Center (NYGC) and the Broad Institute will enable investigators to map the capacity of tumors to develop resistance to drugs and drug combinations. 

Weill Cornell Medicine scientists have built the first 3-D-printed automated synthesis units (ASUs) for producing customized radioactive drugs.

Dr. Silvia Formenti, chair of the Department of Radiation Oncology and the Sandra and Edward Meyer Professor of Cancer Research at Weill Cornell Medicine and radiation oncologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center, has been awarded the 2019 ASTRO Gold Medal by the American Society for Radiation Oncology (ASTRO).

Scientists at Weill Cornell Medicine have developed a system that uses cancer patients’ own cells to evaluate the efficacy of treatments. The scientists used their new testbed to show that a two-drug combination potentially would benefit many patients with acute myeloid leukemia (AML).

Dr. Silvia Formenti has been awarded the 2019 Roentgen Prize for Oncology from the Italian scientific society Accademia Nazionale dei Lincei.

Dr. Lewis Cantley has been awarded a grant from the Gray Foundation to study the genetic mutations that can lead to breast and ovarian cancer, investigating how early-stage precancerous cells can be recognized by the immune system and targeted with preventive or therapeutic cancer vaccines.

A molecular pathway known for responding to cellular stress also produces pain-inducing molecules in immune cells, according to a new study by scientists at Weill Cornell Medicine, Dana-Farber Cancer Institute, Harvard Medical School and Wake Forest University School of Medicine.

A new technology devised by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC) enables the measurement of gene mutations and their effects on gene activity within individual cancer cells biopsied from patients.

A powerful new set of scientific tools developed by Weill Cornell Medicine and New York Genome Center (NYGC) researchers enables them to track the molecular evolution of cancers. 

The work of global oncologists – whose insights and innovations reduce the burden of cancer around the world – has demonstrated value that academic medical leadership should consider when assessing these physicians for professional advancement, according to a commentary by Weill Cornell Medicine investigators.

Weill Cornell Medicine has experienced dynamic growth in its research enterprise over the past five years, an achievement that underscores the institution’s mission to provide patients with the most advanced treatments and therapies.

Long-term spaceflight causes more changes to gene expression than shorter trips, especially to the immune system and DNA repair systems, according to research by Weill Cornell Medicine and NASA investigators as part of NASA’s Twins Study, which followed the only set of identical twin astronauts for more than two years.  

The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland, according to a new study by Weill Cornell Medicine investigators. The findings, published March 28 in Cancer Cell, suggest that the gene, once deleted, helps to promote tumorous growth.

A drug already approved for anemia offers hope for people leukemia.

Consuming the equivalent of one can of soda per day caused mice predisposed to colon cancer to develop larger tumors, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Biochemist Dr. Lewis Cantley is finding increasing evidence of a strong connection between sugar and cancer.

Dr. Manuel Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, has been named chief of the Division of Hematology and Medical Oncology in the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective June 1. 

Treating patients with advanced, metastatic esophageal cancer with an immune-system boosting drug called pembrolizumab, known by its brand name Keytruda, led to regression of tumors in some patients, according to results of a phase 2 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

New studies from Weill Cornell Medicine researchers have revealed the importance of two gene-regulation proteins in the development of common immune cell cancers called lymphomas.

Researchers at Weill Cornell Medicine, in collaboration with investigators at Dana-Farber Cancer Institute, have been awarded a three-year, $1 million grant from the U.S. Department of Defense (DoD) for prostate cancer clinical trials.